Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

PubMed  Google Scholar 

Chaudhary V, Mar F, Amador MJ, Chang A, Gibson K, Joussen AM, et al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025;263:1239–47.

CAS  PubMed  Google Scholar 

Maguire MG, Martin DF, Ying G, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Ophthalmology. 2016;123:1751–61.

PubMed  Google Scholar 

Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305–16.

PubMed  PubMed Central  Google Scholar 

Berkowitz ST, Sternberg P, Feng X, Chen Q, Patel S. Analysis of anti–vascular endothelial growth factor injection claims data in US medicare part B beneficiaries from 2012 to 2015. JAMA Ophthalmol. 2019;137:921.

PubMed  PubMed Central  Google Scholar 

Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252:647–55.

CAS  PubMed  PubMed Central  Google Scholar 

Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, et al. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.

CAS  PubMed  Google Scholar 

Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–46.

CAS  PubMed  Google Scholar 

Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69.

CAS  PubMed  Google Scholar 

Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. THE angiopoietin/tie pathway in retinal vascular diseases: a review. Retina. 2021;41:1–19.

CAS  PubMed  Google Scholar 

Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-world evidence for faricimab in neovascular age-related macular degeneration and diabetic macular edema: a scoping review. Ophthalmol Sci. 2025;5:100744.

PubMed  PubMed Central  Google Scholar 

Samacá-Samacá D, Hernández-Castillo C, Prieto-Pinto L, Rodríguez F, Sardi C, Ocampo H, et al. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. BMJ Open Ophthalmol. 2024;9:e001702.

PubMed  PubMed Central  Google Scholar 

Eckardt F, Lorger A, Hafner M, Klaas JE, Schworm B, Kreutzer TC, et al. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration. Sci Rep. 2024;14:9600.

CAS  PubMed  PubMed Central  Google Scholar 

Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;ume 17:2201–8.

Google Scholar 

Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;ume 16:4041–6.

Google Scholar 

Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262:1151–9.

CAS  PubMed  Google Scholar 

Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024;16:470.

CAS  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database System Rev Implement Rep. 2019;18:2127–33.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [Internet]. Ottawa: Ottawa Hospital Research Institute; [cited 2025 April 29]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Reep NC, Leverett SN, Heywood RM, Baker RT, Barnes DL, Cheatham SW. The efficacy of the Mulligan concept to treat meniscal pathology: a systematic review. Int J Sports Phys Ther. 2022;17:1219–35.

Li Y, Shi Z, Zhao Y, Tan Z, Guo H, Lu Z. Comparative effectiveness and safety among different tip-design hemodialysis long-term catheters: A meta-analysis. J Vasc Access. 2024;25:448–60.

PubMed  Google Scholar 

Stewart WC, Stewart JA, Demos CM, Turner M. Serious adverse event reporting. Ophthalmology. 2009;116:2485.e1.

PubMed  Google Scholar 

Beck RW, Moke PS, Turpin AH, Ferris FL, SanGiovanni JP, Johnson CA, et al. A computerized method of visual acuity testing. Am J Ophthalmol. 2003;135:194–205.

PubMed  Google Scholar 

Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis Virgili G (ed). PLOS ONE. 2017;12:e0183142.

PubMed  PubMed Central  Google Scholar 

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

PubMed  PubMed Central  Google Scholar 

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.

PubMed  Google Scholar 

Aldhanhani AA, Azzam OA, AlAli SH, Almasri KG, Aljneibi SH, Pichi F. Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration. Int Ophthalmol. 2024;44:369.

PubMed  PubMed Central  Google Scholar 

Quah N, Javed KMAA, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;ume 18:1479–90.

Google Scholar 

Muth DR, Fasler KF, Kvanta A, Rejdak M, Blaser F, Zweifel SA. Real-world weekly efficacy analysis of faricimab in patients with age-related macular degeneration. Bioengineering. 2024;11:478.

CAS  PubMed  PubMed Central  Google Scholar 

Ibrahim FNI, Teo KYC, Tan T-E, Chan HH, Chandrasekaran PR, Lee S-Y, et al. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol. 2024;3:1346322.

Google Scholar 

Takahashi H, Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, et al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024;14:9087.

CAS  PubMed  PubMed Central  Google Scholar 

Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29:721–31.

CAS  PubMed  PubMed Central  Google Scholar 

Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43–51.

CAS  PubMed  Google Scholar 

Chi S-C, Weng C-C, Chen S-J, Lin T-C, Chou Y-B, Hwang D-K. The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan. Ophthalmologica. 2024;247:312–21.

CAS  PubMed  Google Scholar 

Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024;38:3059–64.

PubMed  Google Scholar 

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13:2985–97.

PubMed  PubMed Central  Google Scholar 

Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652–6.

PubMed  Google Scholar 

Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024;38:3569–77.

CAS  PubMed  PubMed Central  Google Scholar 

Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life. 2024;14:193.

CAS  PubMed  PubMed Central  Google Scholar 

Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13:21128.

CAS